It could help clinicians gauge the severity or extent of bone spread of cancer in patients with prostate cancer who have already been determined to be high risk for metastasis by the Korle-Bu ALP, PSA, and bone metastasis risk calculator. This evidence concerns the gene KLK3 and prostate carcinoma.